Umbilical Cord Blood

Phase 3Biologic

MMasonic Cancer Center, University of Minnesota

Umbilical Cord Blood is one of 106 biologic programs targeting Autism Spectrum Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

105

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autism Spectrum DisorderActive, not recruiting

InfusionRecruiting

Poor Graft FunctionNot yet recruiting

Lymphatic DiseasesRecruiting

Safety and EfficacyNot yet recruiting

Hematological DiseasesRecruiting

Autism Spectrum DisorderPreclinical

Active, not recruiting

InfusionPreclinical

Recruiting

Poor Graft FunctionPhase 3

Not yet recruiting

Lymphatic DiseasesPreclinical

Recruiting

Safety and EfficacyPreclinical

Not yet recruiting

Hematological DiseasesPreclinical

Recruiting

Competition

Competitive Landscape

131 competitors in Safety and Efficacy

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

3 2

Actemra

Roche

Phase 3

1 3

Humira

RRanbaxy Laboratories Limited

Phase 3

3 4

Rayos

RRoxane Laboratories

Phase 3

3 5

Empaveli

Apellis Pharmaceuticals

Phase 3

2 6

CAB LA

GSK

Phase 3

1 7

Tagrisso

AstraZeneca

Phase 2

3 8

Cytosar

Teva

Phase 2

3 9

Yervoy

Bristol-Myers Squibb

Phase 2

3 10

B/F/TAF

Gilead

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ANot yet recruiting

Safety and Efficacy

NCT07201233

Q1 2028

N/ARecruiting

Hematological Diseases

NCT01962636

PreclinicalRecruiting

Lymphatic Diseases

NCT01451502

Clinical

Trials by Indication[1]

Cerebral Palsy3 trials

Allogenic Umbilical Cord Blood and Erythropoietin Combination Therapy for Cerebral Palsy

Completed·SSung Kwang Medical Foundation·N/A·NCT01193660·105 enrolled

Umbilical Cord Blood Therapy for Cerebral Palsy

Completed·MMinYoung Kim, M.D.·Phase 2·NCT01528436·37 enrolled

FLT-PET Activity Change After Allogeneic Umbilical Cord Blood (UCB) Therapy in Cerebral Palsy

Withdrawn·—·Phase 2·NCT01486732

Hematological Diseases1 trial

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Recruiting·MMasonic Cancer Center, University of Minnesota·N/A·NCT01962636·200 enrolled

Hematologic Malignancies1 trial

Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies

Terminated·UUniversity of Virginia·Phase 2·NCT01622556·6 enrolled

Ischemic stroke1 trial

Study of Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke

Completed·JJoanne Kurtzberg, MD·Phase 2·NCT03004976·79 enrolled

Acute Myeloid Leukemia1 trial

Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid Leukemia

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 1·NCT04687657·20 enrolled

7 more indications

Safety and Efficacy1 trial

Clinical Study on the Safety and Efficacy of Umbilical Cord Blood Infusion in Treating Bone Marrow Suppression .

Not yet recruiting·SShandong Qilu Stem Cells Engineering Co., Ltd.·N/A·NCT07201233·30 enrolled

Stroke1 trial

Combination Therapy of Umbilical Cord Blood and Erythropoietin for Stroke Paients

Unknown status·—·Phase 1/2·NCT04013646·24 enrolled

Complication1 trial

Autologous Cord Blood Infusion for the Prevention and Treatment of Prematurity Complications In Preterm Neonates

Unknown status·PPomeranian Medical University Szczecin·Phase 1·NCT02050971·40 enrolled

Autism Spectrum Disorder1 trial

Umbilical Cord Blood Therapy in a Child With Eosinophilic Duodenitis and Autism Spectrum Disorder: a Case Study

Not yet recruiting·—·N/A·NCT06995274·1 enrolled

Myelodysplastic Syndrome1 trial

Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00604201·31 enrolled

Poor Graft Function1 trial

Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT

Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT05669079·100 enrolled

Lymphatic Diseases1 trial

Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

Recruiting·MMasonic Cancer Center, University of Minnesota·Preclinical·NCT01451502·250 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Umbilical Cord Blood. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Umbilical Cord Blood compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Umbilical Cord Blood. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Masonic Cancer Center, University of Minnesota company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: MMasonic Cancer Center, University of Minnesota

Umbilical Cord Blood

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Trials by Indication[1]

Cerebral Palsy3 trials

Hematological Diseases1 trial

Hematologic Malignancies1 trial

Ischemic stroke1 trial

Acute Myeloid Leukemia1 trial

Safety and Efficacy1 trial

Stroke1 trial

Complication1 trial

Autism Spectrum Disorder1 trial

Myelodysplastic Syndrome1 trial

Poor Graft Function1 trial

Lymphatic Diseases1 trial

References

Drug Info

Quick Facts

Related News